$1.49
-0.02-1.32%
Last update: Nov 5, 5:07 PM
TransCode Therapeutics Inc
RNAZNASDAQ
The average analyst price target for TransCode Therapeutics is $280, 18947.6% above the current price. The one analyst covering it rates it Buy. The latest change came on Apr 16, 2025, when HC Wainwright & Co. lowered its price target on TransCode Therapeutics from $560 to $280 and kept a Buy rating.
Price Target Range — 5 Quarters
Analyst Consensus — 1 Analysts
Rating Trend — Last 9 Months
